EUCTR2007-000418-35-DK进行中（未招募）1 期
A double-blind, randomised, parallel group, placebo-controlled dose finding Phase II study to compare the efficacy and safety of topically applied Avugane™ of different concentrations in subjects with mild to moderate acne vulgaris
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Clinically confirmed diagnosis of facial acne papulopustulosa or acne
- •papulopustulosa et comedonica with a mild to moderate intensity (grade 2 to 8
- •according to the revised Leeds Scale of Acne Grading13) and with at least 12
- •inflammatory lesions
- •2. Patients aged between 18 and 40
- •3. A general good health condition as confirmed by a physical examination and by
- •medical history
- •4. Acceptance of oil-free skin care products
- •5. Acceptance to abstain from any other systemic or topical acne treatment during trial
- •6. Acceptance to abstain from sun bathing and the solarium
- •7. Signed informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Females with positive pregnancy test at baseline
- •2. Females of childbearing potential without using a safe contraceptive measure (e.g.
- •pill, IUD, gestagen depot injection, subdermal implant, hormonal vaginal ring,
- •transdermal depot patch), nursing women
- •3. Diagnosis of any acneiform diseases like exogenous acne, drug induced acne,
- •cosmetic induced acne
- •4. Localisation of acne that requires treatment predominantly on the chest and/or the
- •5. Patients with a personal or family history of cutaneous epithelioma
- •6. History or presence of disorders commonly accepted as contraindications to the
- •treatment with 2-propylpentanoic acid (2-PPA):
- •A.Evidence in the subject's and family medical history of liver diseases or apparent
- •severe functional disorders of liver and pancreas
- •B.Functional disorders of liver with fatal outcome during valproic acid (2-PPA)
- •therapy in siblings.
- •C.Hepatic porphyria
- •D.Present liver disease (bilirubin should be below UNL 22µmol/L, ALT below UNL of
- •60 IU/L, or AST below UNL of 45 U/L)
- •E.Presence of pancreatic dysfunction (p-alpha-amylase below UNL 300 IU/L)
- •F.Decreased renal function (serum creatinine below UNL of 133 µmol/L in men, 115
- •µmol/L in women)
- •G.Haematologic disorder like bleeding disorder or coagulation abnormalities (partial
- •thromboplastin time (PTT) > 1.5 x UNL), bone marrow disorders
- •H.Porphyria, metabolic diseases (especially congenital enzymopathy), systemic
- •lupus erythematosus or hypoproteinaemia
- •I.Hypertension (BP above 140/90)
- •7. Other skin conditions that might interfere with acne diagnosis and/or evaluation
- •(such as facial psoriasis, seborrheic dermatitis, perioral dermatitis and
- •papulo-pustular rosacea)
- •8. History of hypersensitivity to any of the substances in the test drug or in the placebo
- •9. Treatment with any systemic acne drug within the last 3 months prior to the day 1
- •assessment and within 6 months for systemic retinoids
- •10. Treatment with any other topical acne drug within the last 14 days prior to the day
- •1 assessment
- •11. Presence of a significant uncontrolled cardiovascular, neurologic, malignant,
- •psychiatric, respiratory or hypertensive disease
- •12. Recent history of alcohol or any other substance abuse
- •13. Treatment with any experimental drug within 30 days prior to the day 1
- •14. Inability to comply with the study protocol
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomised, parallel group, placebo-controlled dose finding Phase II study to compare the efficacy and safety of topically applied Avugane™ of different concentrations in subjects with mild to moderate acne vulgarisAcne vulgaris of mild to moderate intensityMedDRA version: 9.1Level: LLTClassification code 10000519Term: Acne vulgarisEUCTR2007-000418-35-DETopoTarget A/S72
进行中（未招募）
1 期
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer.Adjuvant breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003839-30-DEAstraZeneca AB1,800
进行中（未招募）
不适用
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer.Adjuvant breast cancerMedDRA version: 17.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003839-30-ESAstraZeneca AB1,320
进行中（未招募）
Unknown
A randomised, double-blind, parallel group, placebo controlled, trial of Bactek for the prevention of lower respiratory tract infections in preterm infantsRespiratory outcomes after premature birth including lower respiratory tract infections and wheeze.RespiratoryISRCTN14019493Cardiff University542
进行中（未招募）
1 期
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2 negative primary breast cancer.EUCTR2013-003839-30-BEAstraZeneca AB1,800